Cytochrome B5 type A alleviates HCC metastasis via regulating STOML2 related autophagy and promoting sensitivity to ruxolitinib

The incidence of hepatocellular carcinoma (HCC) is increasing in the world. However, its role and underlying molecular mechanism in HCC progression remain unclear. We found that CYB5A plays a key role in HCC metastasis by inhibiting the JAK1/STAT3 pathway through binding to STOML2. CYB5A combined wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Hongrui, Liang, Shuhang, Wang, Yan, Zhou, Shuo, Yin, Dalong, Zhang, Shugeng, Wang, Jizhou, Wu, Dehai, Ma, Kun, Liu, Yufeng, Sun, Linmao, Ji, Changyong, Li, Xianying, Zhou, Huanran, Yang, Guangchao, Guo, Xinyu, Cui, Tianming, Li, Zihao, Liu, Yao, Wang, Jiabei, Liu, Lianxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293983/
https://www.ncbi.nlm.nih.gov/pubmed/35851063
http://dx.doi.org/10.1038/s41419-022-05053-8
Descripción
Sumario:The incidence of hepatocellular carcinoma (HCC) is increasing in the world. However, its role and underlying molecular mechanism in HCC progression remain unclear. We found that CYB5A plays a key role in HCC metastasis by inhibiting the JAK1/STAT3 pathway through binding to STOML2. CYB5A combined with STOML2 can predict the outcome of patients. To demonstrate the effect of CYB5A on JAK1 inhibitor function, we applied Ruxolitinib in metastatic tumors with high CYB5A expression and found that it slowed disease progression and prolonged survival in mice. To the best of our knowledge, this study is the first to report the Ruxolitinib effect on the metastatic ability of HCC cells in vivo and in vitro.

Ejemplares similares